

(12) International Application Status Report

Received at International Bureau: 05 September 2017 (05.09.2017)

Information valid as of: 21 January 2019 (21.01.2019)

Report generated on: 15 September 2019 (15.09.2019)

(10) Publication number:

WO2019/031637

(43) Publication date:

14 February 2019 (14.02.2019)

(26) Publication language:

Korean (KO)

(21) Application Number:

PCT/KR2017/008788

(22) Filing Date:

11 August 2017 (11.08.2017)

(25) Filing language:

Korean (KO)

(51) International Patent Classification:

C12Q 1/68 (2006.01); G01N 33/574 (2006.01)

(71) Applicant(s):

INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY [KR/KR]; (Yongbong-dong) 77, Yongbong-ro Buk-gu Gwangju 61186 (KR) (for all designated states)

(72) Inventor(s):

KIM, Il-Chul; #204-1303, 11, Seogang-ro 54beon-gil, Buk-gu, Gwangju 61257 (KR)

KIM, Dong Min; #138-1008 57, Eoeun-ro Yuseong-gu Daejeon 34140 (KR)

CHOI, Seung-Hyun; #106-102, 92, Cheomdanjungang-ro 181beon-gil, Gwangsan-gu, Gwangju 62256 (KR)

LEE, Dong Ju; #110-302, 100, Dongho-ro, Seongdong-gu, Seoul 04724 (KR)

(74) Agent(s):

LEE, Hee Sook; (JS Building, Yeoksam-dong) 9th Fl. 11, Teheran-ro 33 gil, Gangnam-gu Seoul 06141 (KR)

(54) Title (EN): CANCER MARKER GENES FOR P53-NON MUTATIONAL CANCER, AND THERAPEUTIC AGENT SCREENING METHOD

(54) Title (FR): GÈNES MARQUEURS DU CANCER POUR LE CANCER NON MUTATIONNEL P53, ET PROCÉDÉ DE DÉPISTAGE D'AGENT THÉRAPEUTIQUE

(54) Title (KO): p53-비돌연변이 암에 대한 암 마커 유전자 및 치료제 스크리닝 방법

(57) Abstract:

(EN): The present invention relates to cancer marker genes for p53-non mutational cancer, and a therapeutic agent screening method. Although mutations of tumor suppressor gene p53 have been found in most cancers thus far, the screening method of the present invention, based on p53-upstream regulatory genes, for independently regulating the over-expression of MDM2, having clearly been investigated for the first time by the present applicant, enables p53-non mutational cancer-specific anticancer agents to be effectively screened for. In addition, the genes investigated in the present invention (see table 1) are significantly up-regulated in a p53-non mutational cancer state, thereby enabling the occurrence of p53-non mutational cancer to be diagnosed whereas conventional cancer diagnosis has been dependent on the existence of p53 mutations.

(FR): La présente invention concerne des gènes marqueurs du cancer pour le cancer non mutationnel p53, et un procédé de dépistage d'agent thérapeutique. Bien que des mutations du gène p53 suppresseur de tumeur ont été trouvées jusqu'à présent dans la plupart des cancers, le procédé de dépistage selon la présente invention, basé sur des gènes régulateurs amont p53, pour réguler indépendamment la surexpression de MDM2, qui a clairement été étudié pour la première fois par le présent demandeur, permet de dépister efficacement des agents anticancéreux spécifiques du cancer non mutationnels p53. De plus, les gènes étudiés dans la présente invention (voir tableau 1) sont régulés de manière significative dans un état de cancer non mutationnel p53, ce qui permet de diagnostiquer l'apparition d'un cancer non mutationnel p53 alors que le diagnostic du cancer classique a été dépendant de l'existence de mutations de p53.

(KO): 본 발명은 p53-비돌연변이 암에 대한 암 마커 유전자 및 치료제 스크리닝 방법에 대한 것이다. 현재까지 대부분의 암에서 암 억제 유전자인 p53에서 돌연변이가 발견되는 것과 구별하여, 본 발명자에 의하여 최초로 명확히 규명된 p53-독립적으로 MDM2의 과발현을 조절하는 상위 조절 유전자들을 기반으로 하는 본 발명의 스크리닝 방법은 p53-비돌연변이 암 특이적 항암제를 효과적으로 스크리닝 할 수 있다. 뿐만아니라 본 발명에서 규명한 유전자(표 1 참조)들은 p53비돌연변이 암의 상태에서 유의적으로 상향발현되므로, 기존에 암진단이 p53-돌연변이 존재에 의존적이었던것과는 달리 p53-비돌연변이 암 발생에 대한 진단이 가능하다.

International search report:

Received at International Bureau: 09 May 2018 (09.05.2018) [KR]

International Report on Patentability (IPRP) Chapter II of the PCT:

Not available

(81) Designated States:

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

European Patent Office (EPO) : AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

African Intellectual Property Organization (OAPI) : BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG

African Regional Intellectual Property Organization (ARIPO) : BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW

Eurasian Patent Organization (EAPO) : AM, AZ, BY, KG, KZ, RU, TJ, TM